SOUTH SAN FRANCISCO, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the appointment of Adam R. Craig, M.B.B.S., Ph.D., M.B.A. to the newly created position of Executive Vice President, Development and Chief Medical Officer, effective March 1, 2012. In this position, Dr. Craig will oversee the ongoing pivotal Phase 3 VALOR trial of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia (AML) and direct Sunesis’ global development program. Dr. Craig has over 15 years of experience in hematology, oncology and clinical development, most recently as Chief Medical Officer of ChemGenex, a publicly-traded biotechnology company which was acquired by Cephalon in 2011.
